We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $580M
1-Year Est. Return 29.81%
This Fund
S&P 500
This Quarter Est. Return
+38.56%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$228M
AUM Growth
+$47.5M
Cap. Flow
-$5.93M
Cap. Flow %
-2.6%
Top 10 Hldgs %
58.57%
Holding
49
New
15
Increased
12
Reduced
11
Closed
11

Top Buys

Rank Stock Value
1
ARNA
Arena Pharmaceuticals Inc
ARNA
+$7.8M
2
ANAB icon
AnaptysBio
ANAB
+$5.55M
3
NVST icon
Envista
NVST
+$4.69M
4
ORGO icon
Organogenesis Holdings
ORGO
+$3.92M
5
ALDX icon
Aldeyra Therapeutics
ALDX
+$3.69M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$17M
2
HNGR
Hanger Inc.
HNGR
+$8.05M
3
QURE icon
uniQure
QURE
+$5.02M
4
HUM icon
Humana
HUM
+$3.07M
5
ABBV icon
AbbVie
ABBV
+$2.95M

Sector Composition

Rank Sector Weight
1 Healthcare 94.18%
2 Miscellaneous 3.98%
3 Industrials 1.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZBH icon
1
Zimmer Biomet
ZBH
$19.2B
$19.5M 8.54%
133,900
+2,060
+2% +$284K
QURE icon
2
uniQure
QURE
$3.38B
$17M 7.47%
237,500
-91,478
-28% -$5.02M
ARNA
3
DELISTED
Arena Pharmaceuticals Inc
ARNA
$14.9M 6.54%
328,129
+164,996
+101% +$7.8M
KURA icon
4
Kura Oncology
KURA
$1.13B
$14.2M 6.25%
1,036,000
+147,848
+17% +$2.19M
UTHR icon
5
United Therapeutics
UTHR
$22.1B
$14.2M 6.23%
161,195
+28,258
+21% +$2.49M
RETA
6
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$12.9M 5.65%
62,900
+309
+0.5% +$56.4K
IOVA icon
7
Iovance Biotherapeutics
IOVA
$3.63B
$10.8M 4.72%
388,600
+42,451
+12% +$966K
ACIU icon
8
AC Immune
ACIU
$263M
$10.6M 4.65%
1,242,843
-5,610
-0.4% -$37.4K
MGTX icon
9
MeiraGTx Holdings
MGTX
$1.33B
$10.4M 4.55%
517,844
+179,748
+53% +$3.08M
ARQL
10
DELISTED
Arqule Inc
ARQL
$8.99M 3.95%
450,326
+85,529
+23% +$992K
CNC icon
11
Centene
CNC
$32B
$8.98M 3.94%
142,800
-22,200
-13% -$1.2M
ALDX icon
12
Aldeyra Therapeutics
ALDX
$89.9M
$8.3M 3.64%
1,428,277
+638,049
+81% +$3.69M
BMRN icon
13
BioMarin Pharmaceuticals
BMRN
$12.5B
$7.84M 3.44%
92,737
+2,785
+3% +$210K
URGN icon
14
UroGen Pharma
URGN
$2.13B
$7.26M 3.19%
217,686
-107,699
-33% -$2.94M
ARNA
15
CALL
DELISTED
Arena Pharmaceuticals Inc
ARNA
$6.47M 2.84%
+142,400
New +$6.73M
ALBO
16
DELISTED
Albireo Pharma Inc
ALBO
$6.28M 2.76%
247,178
-5,322
-2% -$106K
NVST icon
17
Envista
NVST
$4.36B
$4.89M 2.15%
+165,000
New +$4.69M
PSNL icon
18
Personalis
PSNL
$1.82B
$4.43M 1.95%
406,673
+291,459
+253% +$3.03M
ANAB icon
19
AnaptysBio
ANAB
$1.67B
$3.82M 1.68%
+234,823
New +$5.55M
IMVT icon
20
Immunovant
IMVT
$8.51B
$3.57M 1.57%
+224,702
New +$2.52M
ORGO icon
21
Organogenesis Holdings
ORGO
$224M
$2.97M 1.3%
+617,836
New +$3.92M
EOLS icon
22
Evolus
EOLS
$587M
$2.88M 1.27%
+236,939
New +$3.34M
GYRE icon
23
Gyre Therapeutics
GYRE
$699M
$2.67M 1.17%
52,253
-22,168
-30% -$929K
SBBP
24
DELISTED
Strongbridge Biopharma plc.
SBBP
$2.63M 1.15%
1,258,224
-1,256,848
-50% -$2.41M
RCM
25
DELISTED
R1 RCM Inc. Common Stock
RCM
$2.6M 1.14%
200,000
-208,958
-51% -$2.39M
1
2

Similar funds

SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
CCWM
Correct Capital Wealth Management Clayton, Missouri $580M AUM 16.45% 1-Year Est. Return
CMA
Cedar Mountain Advisors Lake Oswego, Oregon $581M AUM 18.16% 1-Year Est. Return
RIS
Retirement Income Solutions Ann Arbor, Michigan $581M AUM 19.42% 1-Year Est. Return
MFS
McNamara Financial Services Marshfield, Massachusetts $580M AUM 17.89% 1-Year Est. Return
GFI
Global Frontier Investments Charleston, South Carolina $581M AUM 8.55% 1-Year Est. Return
PWM
Praetorian Wealth Management Carmel, California $580M AUM 19.43% 1-Year Est. Return
CA
COFG Advisors Oak Brook, Illinois $579M AUM

Prosight Management's Q4 2019 Portfolio in Review

As of Q4 2019, Prosight Management held 49 positions worth $228M, up 26% from $180M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Prosight Management's Q4 2019 filing shows 15 new, 12 increased, 11 reduced and 11 closed positions. Its largest new stake was AnaptysBio: 234,823 shares worth $3.82M. The largest sale was Bristol-Myers Squibb, an estimated $17M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 97% a quarter earlier, followed by Miscellaneous and Industrials.

  • Prosight Management's largest Q4 2019 buy was AnaptysBio: 234,823 shares worth $3.82M.
  • Prosight Management added most to Arena Pharmaceuticals Inc in Q4 2019, an estimated $7.8M increase.
  • Prosight Management's biggest Q4 2019 reduction was Bristol-Myers Squibb, cutting an estimated $17M.
  • Prosight Management fully exited Hanger Inc. in Q4 2019, selling an estimated $8.05M.
  • Prosight Management's ten largest holdings make up 59% of its $228M portfolio in Q4 2019.
  • Prosight Management opened 15 new positions and closed 11 in Q4 2019.
  • Prosight Management's portfolio value rose 26% quarter-over-quarter to $228M.

Based on Prosight Management's 13F filing for Q4 2019, filed 14 Feb 2020.